INDIVIDUAL PRURITUS AND BILE ACID RESPONSES OVER TIME WITH ODEVIXIBAT TREATMENT: POOLED DATA FROM THE PHASE 3 ASSERT AND ASSERT-EXT STUDIES IN PATIENTS WITH ALAGILLE SYNDROME

<div><p><b>Background: </b>Alagille syndrome (ALGS) is a rare, genetic, multisystem disorder in which cholestatic liver disease is common and that may include clinical manifestations of severe pruritus and elevated bile acids (BAs). The efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, were assessed in patients with ALGS in the phase 3 ASSERT and ASSERT-EXT trials. Using data from these studies, we analyzed the effects of odevixibat on pruritus and BAs over time.</p>

ABILITY OF SECOND HARMONIC GENERATION/TWO-PHOTON EXCITATION FLUORESCENCE IMAGING AND AI ANALYSIS TO DETECT AND QUANTIFY DRUG-INDUCED, PARAMETER-LEVEL CHANGES OF FIBROSIS: RESULTS FROM THE FALCON-1 CLINICAL TRIAL

<div><p><b>Background: </b>FDA recommended histopathological end-points for NASH clinical trials may not be fully evaluated by conventional histological staging. Shorter time frames in NASH trials make it difficult to assess changes in treatment-induced fibrosis with current classification systems. Assessment of specific morphological fibrosis parameters and their quantification in specific zones of NASH-CRN classification, can be done by SHG/TPE-based AI platforms.

EMPAGLIFLOZIN IS EQUALLY EFFECTIVE IN REDUCING LIVER FAT CONTENT IN T2DM PATIENTS AND IN NON-DIABETIC INDIVIDUALS, A RANDOMIZED TRIAL

<div><p><b>Background:</p> </b><p style="font-weight: 400;">This study was performed to examine the effect of empagliflozin on liver fat content in T2DM patients and in nondiabetic individuals, and the relationship between the decrease in liver fat and other metabolic actions of empagliflozin.</p>

TARGETED THERAPY ADAPTED TO TUMOR BIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA OR HEPATOCHOLANGIOCARCINOMA REFRACTORY TO ATEZOLIZUMAB/BEVACIZUMAB

<div><p><b><span data-contrast="auto">Background</span></b><span data-contrast="auto">: The “French Medicine Genomic program 2025” is an academic research program that allows to perform whole-genome/exome/RNA sequencing in advanced cancer refractory to systemic treatments to give access to off-labeled therapies adapted to genomic alterations in clinical practice. We reported results in intermediate and advanced hepatocellular carcinoma (HCC) and hepato-cholangiocarcinoma (H-CCK).

CT-BASED DEEP LEARNING MODEL OF HEPATIC VENOUS PRESSURE GRADIENT FOR PREDICTING THE PROGNOSIS OF HEPATOCELLULAR CARCINOMA WITH TRANSARTERIAL CHEMOEMBOLIZATION (CHANCE-CHESS): A MULTICENTER COHORT STUDY

<div><p><b>Background: </b>To evaluate the impact of CT-based deep learning model of hepatic venous pressure gradient (HVPG) on prognosis of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) and systemic therapy.</p>

AN OPEN-LABEL PARALLEL-GROUP, PHASE II RANDOMISED CONTROLLED TRIAL OF AUTOLOGOUS MONOCYTE DERIVED MACROPHAGE INFUSION IN COMPENSATED CIRRHOSIS

<div><p><b>Background: </b>Cirrhosis is characterised by severe liver fibrosis, organ dysfunction and liver-related complications. Presently, there are no approved anti-fibrotic or pro-regenerative therapies for cirrhosis. Preclinical studies have shown bone marrow-derived macrophage injections can resolve hepatic fibrosis, stimulate regeneration and reduce inflammation.

SAFETY OF DOACS IN PATIENTS WITH CHILD-PUGH CLASS C CIRRHOSIS AND ATRIAL FIBRILLATION

<div><p><strong>Background</strong>: Anticoagulation (AC) is the mainstay of thromboprophylaxis for stroke prevention in atrial fibrillation (AF) and is recommended. Cirrhosis is a risk factor for AF development; hence, AF is common in patients with cirrhosis. The hemostatic pathways in cirrhosis are imbalanced which makes their response to anticoagulation unpredictable. While Direct-Oral Anticoagulants (DOACs) are shown to be safe and effective in patients with AF without cirrhosis, they are hardly studied in patients with cirrhosis.

PSYCHOSOCIAL NOT CLINICAL FACTORS PREDICT LIVER TRANSPLANT LISTING AMONG SAFETY-NET REFERRALS

<div><p><b>Background: </b>Due to socioeconomic and healthcare access challenges, safety-net patients with liver disease face substantial disadvantages. Little is known about which factors – including psychosocial factors – impact listing for liver transplantation (LT) among the safety-net population.</p>

INHIBITION OF GUT BACTERIAL BILE SALT HYDROLASES (BSHS) ATTENUATES EARLY NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND NASH WITH FIBROSIS

<div><p><b>Background:</p> </b><p>Increased intestinal permeability is one of the multiple hits in the pathogenesis of non-alcoholic steatohepatitis (NASH). Bile salt hydrolase (BSH) is a gut bacterial enzyme that hydrolyzes conjugated bile acids (BAs) into unconjugated BAs. Our previous study reported that inhibition of BSH with a gut-restricted small molecule inhibitor, AAA-10, increased conjugated BAs and prevented the development of intestinal permeability and liver steatosis in an early onset, diet-induced rat steatosis model.

SINGLE-NUCLEI TARGETED DNA SEQUENCING REVEALS PATTERNS OF SELECTIVE CLONAL EVOLUTION DURING HEPATOCELLULAR CARCINOMA (HCC) PROGRESSION

<div><p><b>Background:</p> </b><p><span style="font-weight: 400;">Single-cell technologies address the critical issue of tumor heterogeneity in hepatocellular carcinoma (HCC), but face challenges such as complex cell isolation, need for fresh samples, and limited genomic coverage from low DNA content. To overcome these obstacles, we developed a robust workflow for single-nucleus DNA sequencing from frozen HCC tissue, utilizing a custom amplicon panel to elucidate genetic events in HCC clonal evolution.</span></p>

Subscribe to